Literature DB >> 32205122

Different Scan Protocols Affect the Detection Rates of Diabetic Retinopathy Lesions by Wide-Field Swept-Source Optical Coherence Tomography Angiography.

Ying Zhu1, Ying Cui2, Jay C Wang3, Yifan Lu3, Rebecca Zeng4, Raviv Katz3, David M Wu5, Dean Eliott6, Demetrios G Vavvas6, Deeba Husain6, Joan W Miller6, Leo A Kim6, John B Miller7.   

Abstract

PURPOSE: To compare different scan protocols of wide-field swept-source optical coherence tomography angiography (SS-OCTA) for the detection of diabetic retinopathy (DR) lesions.
DESIGN: Comparison of diagnostic approaches.
METHODS: A prospective, observational study was conducted at Massachusetts Eye and Ear from December 2018 to July 2019. Proliferative diabetic retinopathy (PDR), nonproliferative diabetic retinopathy (NPDR), and diabetic patients without DR were included. All patients were imaged using SS-OCTA using the following scan protocol: 3- × 3-mm Angio centered on the fovea; 6- × 6-mm Angio centered on the fovea and the optic disc; 15- × 9-mm Montage; and 12- × 12-mm Angio centered on the fovea and the optic disc. Images were independently evaluated by 2 graders for the presence or absence of DR lesions including microaneurysms, intraretinal microvascular abnormalities, neovascularization, nonperfusion areas, venous looping, and hard exudates. All statistical analyses were performed using commercial software.
RESULTS: A total of 176 eyes in 119 participants were included in the study. The detection rate of neovascularization on 6- × 6-mm Angio centered on the fovea was approximately one-half that on 15- × 9-mm Montage (P < .05) imaging. Combining 6- × 6-mm Angio imaging centered on the fovea and the optic disc could increase the rate to approximately two-thirds (P < .05). The 12- × 12-mm Angio imaging centered on the combination of fovea and optic disc had detection rates comparable to those of 15- × 9-mm Montage imaging for all DR lesions (P > .05). For microaneurysms, 6- × 6-mm Angio had better performance than 15- × 9-mm Montage (P < .05).
CONCLUSIONS: Wide-field SS-OCTA images were useful in detecting DR lesions. The 12- × 12-mm Angio imaging centered on the fovea and on the optic disc may be an optimal balance between speed and efficacy for evaluation of DR in clinical practice.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32205122     DOI: 10.1016/j.ajo.2020.03.004

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Widefield Swept-Source OCT Angiography Metrics Associated with the Development of Diabetic Vitreous Hemorrhage: A Prospective Study.

Authors:  Ying Cui; Ying Zhu; Edward S Lu; Rongrong Le; Inês Laíns; Raviv Katz; Jay C Wang; Itika Garg; Yifan Lu; Rebecca Zeng; Dean Eliott; Demetrios G Vavvas; Deeba Husain; Joan W Miller; Leo A Kim; David M Wu; John B Miller
Journal:  Ophthalmology       Date:  2021-02-26       Impact factor: 14.277

2.  Comparison of widefield swept-source optical coherence tomography angiography with ultra-widefield colour fundus photography and fluorescein angiography for detection of lesions in diabetic retinopathy.

Authors:  Ying Cui; Ying Zhu; Jay C Wang; Yifan Lu; Rebecca Zeng; Raviv Katz; Filippos Vingopoulos; Rongrong Le; Inês Laíns; David M Wu; Dean Eliott; Demetrios G Vavvas; Deeba Husain; Joan W Miller; Leo A Kim; John B Miller
Journal:  Br J Ophthalmol       Date:  2020-06-26       Impact factor: 5.908

Review 3.  Ultrawide Field Imaging in Diabetic Retinopathy: Exploring the Role of Quantitative Metrics.

Authors:  Mohamed Ashraf; Jerry D Cavallerano; Jennifer K Sun; Paolo S Silva; Lloyd Paul Aiello
Journal:  J Clin Med       Date:  2021-07-27       Impact factor: 4.964

Review 4.  Optical Coherence Tomography Angiography in Diabetic Patients: A Systematic Review.

Authors:  Ana Boned-Murillo; Henar Albertos-Arranz; María Dolores Diaz-Barreda; Elvira Orduna-Hospital; Ana Sánchez-Cano; Antonio Ferreras; Nicolás Cuenca; Isabel Pinilla
Journal:  Biomedicines       Date:  2021-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.